Taysha Gene Therapies (TSHA) Income towards Parent Company: 2022-2025
Historic Income towards Parent Company for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$30.9 million.
- Taysha Gene Therapies' Income towards Parent Company fell 29.62% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 15.66%. This contributed to the annual value of -$84.6 million for FY2024, which is 14.56% down from last year.
- Taysha Gene Therapies' Income towards Parent Company amounted to -$30.9 million in Q3 2025, which was down 23.92% from -$24.9 million recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Income towards Parent Company registered a high of -$15.0 million during Q4 2023, and its lowest value of -$55.1 million during Q4 2022.
- In the last 3 years, Taysha Gene Therapies' Income towards Parent Company had a median value of -$20.1 million in 2025 and averaged -$21.3 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 72.69% in 2023, then tumbled by 43.36% in 2024.
- Taysha Gene Therapies' Income towards Parent Company (Quarterly) stood at -$55.1 million in 2022, then spiked by 72.69% to -$15.0 million in 2023, then fell by 21.39% to -$18.3 million in 2024, then fell by 29.62% to -$30.9 million in 2025.
- Its Income towards Parent Company was -$30.9 million in Q3 2025, compared to -$24.9 million in Q2 2025 and -$20.1 million in Q1 2025.